Back to search results

Study on Pectoserratus Block for Shoulder Replacement Pain

This study is looking at ways to improve pain control after total shoulder replacement surgery. Currently, an interscalene block (ISB) is used to reduce pain, but many patients still need strong pain medications. This research is testing if adding another type of nerve block, called a pectoserratus block, to the standard ISB can further reduce pain and the need for opioid medications. The pectoserratus block uses either bupivacaine (a numbing medicine) or saline (saltwater) and is given with ultrasound guidance. The study aims to enroll 110 participants between 18 and 85 years old who are having total shoulder replacement surgery. We will measure the maximum pain you experience 24 hours after surgery. The study is currently unclear on its recruitment status.

Study design
This interventional study plans to enroll 110 participants. It compares adding bupivacaine to the standard pain block versus adding saline.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Pain levels will be measured at 24 hours after surgery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06143306

Addition of a Pectoserratus Block to Interscalene Block in Patients Undergoing Total Shoulder Replacement

Recruiting
PHASE4Ages 18–85InterventionalSupportive care
University of Minnesota
~110 participants
Updated 2026-03-17 on ClinicalTrials.gov
What's tested:bupivacaine.Saline

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Maximum pain
Measured over 24 hours postop

Conditions

Total Shoulder Arthroplasty

Explore related trials

Reverse prosthetic total arthroplasty of shoulder

NCT06143306

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Minnesota

    Minneapolis, Minnesotastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Jacob Hutchins, MD, MHA · PRINCIPAL_INVESTIGATOR · University of Minnesota

Who to contact

Candace Nelson
[email protected]
612-625-7116
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients undergoing total shoulder arthroplasty or reverse total shoulder arthroplasty;
Patients aged 18-85 years old.

Exclusion

Patients who have an exclusion to regional anesthesia such as pre-existing nerve damage to their brachial plexus or infection at the site of injection.
Patients who have exclusion to interscalene blockade such as severe lung disease.
Non-English speakers will be excluded because pain scales are not validated in other languages and there is lack of standardization of pain reporting.
Pregnant patients
Patients who are currently using opioids and patients with a diagnosis of chronic pain will be excluded.

What this trial measures

  • Maximum pain24 hours postop

    This measurement is the highest pain score within the first 24 hours post-op. Please change abbreviations for time frames to minutes, hours and years respectively. And the Scale is 0 being no pain to 10 being worst pain.